<DOC>
	<DOCNO>NCT00147420</DOCNO>
	<brief_summary>Previous research confirm hemorrhage among commonly encounter pregnancy complication Tibet Autonomous Region ( TAR ) . This trial test effectiveness traditional Tibetan drug ( Zhi Byed 11 ) vs. misoprostol prevent postpartum hemorrhage ( PPH ) among woman deliver vaginally three hospital Lhasa , TAR .</brief_summary>
	<brief_title>RCT Zhi Byed 11 ( ZB11 ) Versus Misoprostol Tibet</brief_title>
	<detailed_description>Post-partum hemorrhage ( PPH ) one main direct cause maternal mortality , particularly rural area low access skilled provider , blood bank , surgical facility . In addition mortality , PPH also account great number morbidity , include anemia , renal pulmonary problem , fatigue , decrease resistance infection , major health problem affect woman TAR . Clinical research rare Tibetan Autonomous Region ( TAR ) People 's Republic China . This trial estimate effect prophylactic oral ZB 11 administer begin second stage labor versus prophylactic oral misoprostol , administer third stage labor , reduce incidence postpartum hemorrhage ( define measure blood loss &gt; 500 cc ) . An observational postpartum blood measurement study conduct . This include data collection delivery three TAR hospital Lhasa , pilot consent form data collection instrument , train use plastic drape measurement postpartum blood loss . This randomized , double mask trial test hypothesis misoprostol effective ZB11 reduce frequency postpartum hemorrhage ( define either measure blood loss &gt; 500cc administration open label uterotonics within one hour observation period delivery ) . An original sample 848 woman increase 967 consent woman randomize ( 1:1 ) ZB11 misoprostol arm . Since ZB 11 misoprostol must administer different time , participant receive either active ZB 11 correspond placebo full dilation active misoprostol correspond placebo immediately follow birth baby . The effectiveness study drug estimate postpartum blood loss measure enrolled woman blood collection drape .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Misoprostol</mesh_term>
	<criteria>Inclusion Exclusion Criteria Adult , pregnant woman satisfy follow criterion may enrol study . Pregnant woman : delivering study period one three hospital 18 year age old time delivery 28 week pregnant likely normal vaginal delivery singleton intrauterine pregnancy vertex presentation either early labor anticipation induction labor , whose fetus alive ( heart rate &gt; 100bpm ) time screen able give inform consent . Any following criterion exclude woman study participation : preterm labor ( &lt; 28 week ) previous plan cesarean delivery current multiple gestation active hemorrhage severe anemia ( Hgh &lt; 7 ) hypertension ( persistent BP &gt; 140/90 great OR hypertension require treatment ) [ criterion omit midstudy ] maternal history bleed disorder know allergy medication ( severe chronic allergic condition ) body temperature great 38ÂºC asthma ( asthma require treatment ) mental disability unable focus consent process due imminent delivery To eligible participation care provider , participant must satisfy follow criterion : obstetrical care provider pregnant woman study least 18 year age must physician nurse midwife</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Tibet</keyword>
	<keyword>Third Stage Labor</keyword>
	<keyword>Post Partum Hemorrhage</keyword>
	<keyword>Misoprostol</keyword>
	<keyword>Zhi Byed 11</keyword>
	<keyword>Global Network</keyword>
</DOC>